Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Adhera Therapeutics Inc (ATRX) Com Stk USD0.006

Sell:$0.17 Buy:$0.17 Change: $0.012 (7.50%)
Market closed |  Prices as at close on 21 September 2021 | Switch to live prices |
Change: $0.012 (7.50%)
Deal now Deal for just £11.95 per trade in a Fund and Share Account
Market closed |  Prices as at close on 21 September 2021 | Switch to live prices |
Change: $0.012 (7.50%)
Market closed |  Prices as at close on 21 September 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Adhera Therapeutics, Inc., formerly Marina Biotech, Inc., is a specialty pharmaceutical company that provides patient centric treatment for hypertension. The Company develops and commercializes pharmaceutical therapies and provides technology to improve patient outcomes. It is also focused on developing and commercializing late-stage, non-addictive pain therapeutics. It provides Celecoxib-Lisinopril fixed dose combination (IT-102) and Celecoxib-Olmesartan fixed dose combination (IT-103), which are designed to control the side-effect of edema that prohibits the drug from being prescribed at higher doses. IT-102 targets a population requiring angiotensin converting enzyme (ACE) inhibitors, such as lisinopril and IT-103 targets a population requiring olmesartan. The Company is also focused on commercializing perindopril arginine and amlodipine besylate (PRESTALIA) through DyrctAxess, which is a patient-centric treatment platform.

Contact details

P.O. Box 2161
United States
+1 (919) 5785901

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$2.09 million
Shares in issue:
13.04 million
Off Exchange
United States
US dollar

Key personnel

  • Andrew Kucharchuk
    Chairman of the Board, Chief Executive Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.